NovaBridge Biosciences (NBP) Revenue (2022 - 2023)
NovaBridge Biosciences (NBP) reported Revenue of $5000.0 for Q4 2023, down 99.67% year-over-year from $1.5 million in Q4 2022, and down 98.41% quarter-over-quarter from $315000.0 in Q3 2023.
NovaBridge Biosciences (NBP) Revenue (2022 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has 2 years of Revenue data on file, last reported at $5000.0 in Q4 2023.
- Revenue for Q4 2023 came in at $5000.0, down 99.67% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.0 million (changed N/A YoY), and the FY2023 annual result was $632000.0, down 59.25% from the prior year.
- Revenue fell to $5000.0 in Q4 2023 per NBP's latest filing, from $315000.0 in the prior quarter.
- Over five years, Revenue peaked at $1.5 million in Q4 2022 and troughed at $5000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5,000.00 |
| Sep 30, 2023 | 315,000.00 |
| Jun 30, 2023 | 159,000.00 |
| Dec 31, 2022 | 1.50 Mn |